Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 72.4% in May

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a large drop in short interest in May. As of May 15th, there was short interest totaling 19,453 shares, a drop of 72.4% from the April 30th total of 70,535 shares. Based on an average daily trading volume, of 159,209 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.0% of the company’s shares are sold short.

Institutional Trading of Xtant Medical

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Xtant Medical during the 2nd quarter worth approximately $26,000. Tradition Wealth Management LLC purchased a new stake in Xtant Medical during the 4th quarter worth approximately $79,000. Wiregrass Investment Management LLC purchased a new stake in Xtant Medical during the 4th quarter worth approximately $81,000. Mink Brook Asset Management LLC grew its position in Xtant Medical by 125.8% during the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Finally, Nano Cap New Millennium Growth Fund L P purchased a new stake in Xtant Medical during the 4th quarter worth approximately $220,000. Hedge funds and other institutional investors own 69.33% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on XTNT shares. Craig Hallum restated a “buy” rating on shares of Xtant Medical in a report on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $1.00 price target on shares of Xtant Medical in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Xtant Medical currently has a consensus rating of “Buy” and an average target price of $1.00.

Xtant Medical Stock Up 2.2%

Shares of Xtant Medical stock opened at $0.47 on Friday. The firm’s 50 day moving average price is $0.51 and its 200-day moving average price is $0.61. The company has a quick ratio of 1.64, a current ratio of 3.34 and a debt-to-equity ratio of 0.17. Xtant Medical has a 52-week low of $0.44 and a 52-week high of $0.95. The company has a market cap of $65.92 million, a P/E ratio of 47.05 and a beta of -0.11.

Xtant Medical (NYSEAMERICAN:XTNT) last released its earnings results on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share for the quarter, hitting the consensus estimate of ($0.02). The company had revenue of $20.88 million for the quarter, compared to the consensus estimate of $20.16 million. Xtant Medical had a net margin of 1.50% and a return on equity of 3.68%.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.